PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW’26, the 9th Conference of the ...
Opportunities in the Abrysvo market are driven by unmet RSV vaccine needs, aging populations, rising RSV cases, and expanded adult immunization programs. Growth is supported by enhanced vaccine access ...
GSK (NYSE:GSK) is one of the best value stocks to buy now. On February 17, GSK released new real-world evidence showing that ...
According to GSK, an FDA approval decision is expected in the first half of 2026. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) ...
Tony Wood, Chief Scientific Officer, GSK: “We are pleased with ACIP's recommendation to expand the benefits of RSV immunization to more than 13 million adults aged 50-59 who are at increased risk for ...
Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known interactions ...
Final data from these trials will be submitted to the Food and Drug Administration to support a label expansion to include these patient populations. Preliminary data were announced from 2 clinical ...
Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a brand-name intramuscular injection that’s prescribed to help prevent a lung infection that’s caused by RSV infection in adults. The cost ...
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons in ...
After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...
Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results